<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The identification of patients at higher risk of recurrence after primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> resection is currently one of the challenges facing medical oncologists </plain></SENT>
<SENT sid="1" pm="."><plain>Circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell (CTC) may represent a surrogate marker of an early spread of disease in patients without overt <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-seven high-risk stages II-III <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients were evaluated for the presence of CTC </plain></SENT>
<SENT sid="3" pm="."><plain>Enumeration of CTCs in 7.5 ml of blood was carried out with the FDA-cleared CellSearch system </plain></SENT>
<SENT sid="4" pm="."><plain>CTC count was performed after <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> resection and before the start of adjuvant therapy </plain></SENT>
<SENT sid="5" pm="."><plain>CTC was detected in 22 % of patients with a significant correlation with regional lymph nodes involvement and stage of disease </plain></SENT>
<SENT sid="6" pm="."><plain>No significant correlation was found among the presence of CTC and other clinicopathological parameters </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest that CTCs detection might help in the selection of high-risk <z:e sem="disease" ids="C0677948" disease_type="Neoplastic Process" abbrv="">stage II colorectal cancer</z:e> patient candidates for adjuvant chemotherapy </plain></SENT>
</text></document>